Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074334 · ClinicalTrials.gov registry record · Phase 1
TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00074334 is a Phase 1 study that was terminated before completion, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 3 participants.
The verdict
NCT00074334, a Phase 1 study, was terminated before completion, sponsored by Pediatric Brain Tumor Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: The TP-38 toxin can locate tumor cells and kill them without harming normal cells. Giving TP-38 toxin directly into the tumor may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of TP-38 toxin administered directly into the brain and to see how well it works in treating young patients with recurrent or progressive supratentorial high-grade glioma.
Interventions
- PROCEDURE conventional surgery
- BIOLOGICAL TGFa-PE38 immunotoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00074334
The ClinicalTrials.gov registry entry for NCT00074334 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which conventional surgery is the first listed.
NCT00074334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00074334 about?
NCT00074334 is a clinical study titled "TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma". RATIONALE: The TP-38 toxin can locate tumor cells and kill them without harming normal cells. Giving TP-38 toxin directly into the tumor may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of TP-38 toxin administered directly into the brain and to se...
What is the current status of trial NCT00074334?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2004-05. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00074334?
The interventions under investigation include: conventional surgery (PROCEDURE), TGFa-PE38 immunotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00074334?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.